GERD Cough Relief: Endoscopic Treatment Outcomes

Patients with gastroesophageal reflux disease (GERD) who also suffer from chronic cough face a difficult reality. Their cough is often resistant to standard treatments. A new study identifies the specific factors that predict whether a minimally invasive endoscopic procedure will finally resolve that cough. Researchers Xinhui Fang, Lida Zhang, and Songze Ding built a predictive model that is 96.7% accurate in forecasting treatment success.

### How Researchers Identified Predictive Factors
The study, published in *Frontiers in Medicine*, analyzed clinical data from 200 patients with GERD and chronic cough who underwent endoscopic minimally invasive treatment. The goal was to find what separated the 165 patients whose coughs improved from the 35 whose coughs persisted. Improvement was defined as a 50% or greater reduction in a validated cough score after treatment.

The team used a two-step, machine learning-augmented approach. First, they applied two different algorithms—LASSO regression and XGBoost—to screen all potential patient variables. This “intersection screening” method identified seven factors common to both models: age, cough duration, ineffective esophageal motility, DeMeester score (a measure of acid reflux severity), pepsin level, fractional exhaled nitric oxide (FeNO), and secretory immunoglobulin A (SIgA). These seven were then analyzed with traditional multivariate logistic regression to determine independent predictors.

### The Six Key Predictors of Treatment Outcome
The final analysis distilled the list to six independent drivers of outcome. Three are directly related to the mechanics and severity of reflux:
* **Ineffective Esophageal Motility:** This was the strongest predictor. Patients with weak, uncoordinated esophageal contractions were 27 times more likely to have a persistent cough.
* **DeMeester Score:** A higher score, indicating more severe acid exposure, increased the risk of ongoing cough.
* **Pepsin:** This stomach enzyme, found in higher levels in the airways of the non-relief group, directly irritates the throat and lungs.

The other three factors point to the airway’s own condition and immune response:
* **Cough Duration:** A longer history of chronic cough before treatment reduced the chance of success.
* **Fractional Exhaled Nitric Oxide (FeNO):** Elevated FeNO is a marker of airway inflammation, commonly seen in conditions like asthma. Its presence here suggests a more inflamed, hypersensitive airway that is harder to calm.
* **Secretory Immunoglobulin A (SIgA):** This immune protein in saliva acts as the first line of defense in the mucosa. Higher SIgA levels were protective, linked to a greater likelihood of cough resolution.

### A Clinical Model with High Accuracy
Using these six factors, the researchers constructed a nomogram—a visual calculation tool a doctor can use to estimate an individual patient’s probability of successful cough relief. The model’s performance was robust. Internal validation using 1,000 Bootstrap samples showed an area under the curve (AUC) of 0.967, indicating excellent ability to distinguish between patients who will and will not respond.

The calibration curve also showed strong agreement, meaning the predicted probabilities closely matched the actual observed outcomes in the study. This suggests the tool is reliable, not just for the study group, but potentially for new patients as well.

### Implications for Patient Care and Respiratory Health
These findings shift the focus from treating GERD as a single condition to addressing a multi-system problem. For patients considering endoscopic treatment, pre-procedure testing for esophageal motility, pepsin, and FeNO could provide a clear prognosis. A poor predicted outcome might steer a patient and their doctor toward more aggressive multi-modal therapy or different interventions first.

The role of SIgA is particularly interesting. As a marker of mucosal immune health, it opens questions about whether supporting this system could improve outcomes. While the study doesn’t prove causation, it aligns with broader concepts of how respiratory health is supported by foundational practices. For instance, chronic stress is known to suppress SIgA, while certain breathing practices may support immune regulation. Our article on Breath & Immunity: Cytokines & Slow Breathing Benefits explores these connections. Furthermore, poor respiratory muscle function can affect pressure dynamics that worsen reflux; improving inspiratory muscle strength may be a useful adjunct for some patients.

The link between chronic cough, airway inflammation (FeNO), and stress is also critical. A persistent cough creates a cycle of physical irritation and psychological distress, which can heighten airway sensitivity. Managing this stress component is vital, and structured breathwork for stress relief can be a key part of breaking that cycle. For patients whose cough-related anxiety disrupts sleep, cross-referencing with non-drug interventions like those discussed in the guide to Cognitive Behavioral Therapy for Insomnia on SleepScience could be valuable.

This research, available in full via DOI: 10.3389/fmed.2026.1796830, moves the management of GERD-related chronic cough toward precision medicine. By identifying the specific pathological threads—mechanical, inflammatory, and immunological—that need to be cut, it gives clinicians a powerful map for guiding treatment and setting realistic expectations for recovery.